Arthur M. Fishman, M.D. is a board-certified ophthalmologist with Eye Surgery Associates. Dr. Fishman is a specialist in cataract/refractive surgery. He attended Tulane University, graduating with honors and serving as Vice President for Finance of his undergraduate class. He received his Medical Degree in 1981 from Temple University School of Medicine in Philadelphia, PA. Dr. Fishman served his internal medicine internship at Philadelphia’s Albert Einstein Medical Center. Dr. Fishman completed his ophthalmology residency as chief resident at the New York College of Medicine in 1985. He is a Diplomate of the American Board of Ophthalmology.
Dr. Fishman was in private practice until he joined Eye Surgery Associates in 1994. Dr. Fishman has served as Chief for the Department of Ophthalmology at Memorial Regional Hospital in Hollywood, FL and Memorial West Hospital in Pembroke Pines, FL. Dr. Fishman currently serves as Chairman of the Board at the Surgery Center of Weston in Weston, FL.
Dr. Fishman specializes in cataract and intraocular lens implantation surgery. He has performed well over 25,000 of these procedures. Dr. Fishman was a pioneer in modern small incision, no-stitch, topical anesthesia surgery with the use of only eye drops to perform the cataract procedure. In 2004, Dr. Fishman was selected to be one of the first ophthalmologists in the state of Florida to utilize the Crystalens accommodative intraocular lens implant to provide his patients with a solution to presbyopia or problems with reading. Dr. Fishman’s patients benefit from the ReSTOR and Tecnis multifocal intraocular lenses, with the ability to see at distance, intermediate, and close up without the use of spectacle correction or contact lenses.
Dr. Fishman is constantly seeking ways to make procedures for cataract removal safer, more effective and even more predictable through the use of advanced technology. He now offers Bladeless Laser Cataract Surgery with the newest advances and precision of the femtosecond laser. Dr. Fishman’s expertise, skill, and techniques interfaced with the latest technology and advanced intraocular lens implants allow patients to achieve their desired vision correction goals and resume their lifestyles in just a few days after surgery.
Dr. Fishman has been actively involved as the Principal Investigator in several key clinical research trials. His research findings have been presented to the U.S. Food and Drug Administration and have resulted in the advancement of intraocular lens implants, surgical solutions, and ocular medications. He has been invited to lecture about his clinical trial experiences and remains dedicated to the advancement of safer, more effective, and more predictable patient outcomes and to the enrichment of his profession.
Dr. Fishman is a member of the American Academy of Ophthalmology, the Florida Society of Ophthalmology, the Miami Ophthalmological Society, and currently serves as a managing partner for Eye Surgery Associates.
Dr. Fishman specializes in cataract and intraocular lens implantation surgery. He has performed well over 25,000 of these procedures.
Dr. Fishman is a member of the American Academy of Ophthalmology, the International Society of Refractive Surgeons, the Florida Society of Ophthalmology, the Miami Ophthalmological Society, and currently serves as a managing partner for Eye Surgery Associates. Dr. Fishman enjoys golf, horse racing and spending time with his wife, Debbie and their three sons.
2014 – Principal Investigator, Bausch + Lomb, #842
A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
2014 – Sub-investigator, Alcon Research, Ltd. C-12-067
Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0.3% For improvement In Clinical Outcomes Among Diabetic.
2013 – Principal investigator, Alcon Research, Ltd. C-11-020
Post Approval Study of the AcrySof IQ Toric High Cylinder Power IOL Models SN6T6-SN6AT9
2013 – Principal Investigator, Alcon Research, Ltd. C-09-076
Clinical Investigation of AcrySof IQ Monofocal Toric Intraocular Lens Model SN6AT2
2012 – Principal Investigator, Bausch + Lomb, Inc., #793
A Phase 3, Multicenter, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group. Study to Assess the Efficacy and Safety of Mapracorat in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery
2012 – Sub- Investigator, Alcon Research, Ltd. C-11-034
A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003% Compared to TRAVATAN in Patients with Open-Angle Glaucoma or Ocular Hypertension.
2012 – Sub-Investigator, Alcon Research, Ltd. C-10-039
A Three-Month, Randomized, Double-Masked, Parallel Group Study with a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension.
2011 – Principal Investigator, Alcon Research, Ltd. C-11-003
Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% Compared to Nepafenac Ophthalmic Suspension 0.1% and Vehicle for Prevention and Treatment of Ocular Inflammation and Pain associated with Cataract Surgery.
2011 – Principal Investigator, Bausch & Lomb, Inc. #663
A Phase 3, Multicenter, Double-Masked, Vehicle-Controlled, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation after Cataract Surgery. (ANGEL STUDY)
2011 – Principal Investigator, Alcon Research, Ltd. C-09-005
Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain after Cataract Surgery
2010 – Sub-Investigator, EMD Serono 27919 / 27918 / 28850 / 27938
A phase III, double-blind, placebo-controlled, Randomized Trial to Determine the Efficacy of a Low (50 mg/day) and High (100 mg/day) Dose of Safinamide, as Add-on Therapy, in Subjects with Early Idiopathic Parkinson’s Disease treated with a Stable Dose of a Single Dopamine Agonist.
2010 – Principal Investigator, Alcon Research, Ltd. C-09-055
Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain after Cataract Surgery.
2010 – Principal Investigator, Bausch & Lomb Protocol #577
A Randomized, Multicenter, Double-Masked, Parallel- Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Gel, 0.5% versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery.
2010 – Principal Investigator, Bausch & Lomb Protocol #603
A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6%, BID Compared to vehicle in the Treatment of Bacterial Conjunctivitis.
2010 – Principal Investigator, Bausch & Lomb Protocol #588
A Randomized, Multicenter, Double-Masked, Parallel- Group Dose Ranging Clinical Safety and Efficacy Evaluation of BOL-303242-X versus Vehicle for the Treatment of Inflammation Following Cataract Surgery.
2009 – Investigator, University of Pennsylvania School of Medicine, Center for Preventive Ophthalmology and Biostatistics. Dry Eye Evaluation and Management.
2009 – Sub-investigator, Alcon Research, Ltd. Protocol # C-07-43
A Clinical Safety and Efficacy Comparison of Nevanac 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients.
2009 – Principal Investigator, ISTA Pharmaceuticals. Protocol #CL-S&E-120508-1-P. Efficacy and Safety of Bromfenac Ophthalmic Solution QD versus Placebo QD for Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery.
2008 – Bausch & Lomb. Principal Investigator. Protocol #526
A Randomized, Multi-Center, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Ointment, 0.5% versus Vehicle for the Treatment of Inflammation Following Cataract Surgery.
2008 – Principal Investigator, Allergan Research, Protocol #191578-005-01
A Multi-center, Double Masked, Randomized Parallel Group Study Evaluating the safety and Efficacy of a New Formulation of Ketorolac Tromethamine 0.45% Ophthalmic Solution Compared with Vehicle Administered Preoperatively and Twice-Daily Postoperatively for Two Weeks for the Treatment of Anterior Segment Inflammation, Pain and Inhibition of Surgically Induced Miosis Following Cataract Extraction with Posterior Chamber Intraocular Lens (IOL) Implantation.
2007 – Sub-investigator, Evolutec Ltd. Protocol #EVOL-PRO-06-024.
A Multi-Center, Randomized, Double Masked, Placebo and Positive Controlled, Parallel-Group Study Evaluating the Safety and Efficacy rEV131 2.5mg/mL, rEV131 1.25.mg/mL, and rEV131 0.625mg/mL for the Treatment for the Treatment of Ocular Inflammation after Cataract Surgery.
2006 – Principal Investigator, Alcon Research, Ltd., Protocol #C-05-23
A Double-Masked, Parallel-Group, Randomized, Single-Dose Bioequivalence Study of Tobradex AF Suspension and Tobradex Ophthalmic Suspension.
2006 – Principal Investigator, Alcon Research, Ltd., Protocol#C-05-20
A 3-Month Clinical Safety Comparison of Nevanac 0.1% to Acular LS 0.4% and Vehicle Following Cataract Surgery.
2005 – Principal Investigator, Alcon Research, Ltd., Protocol #C-05-43
A Single-Masked, Multi-Center Pharmacokinetic Pilot Study of Tobradex AF Suspension Formulations.
2003 – Principal Investigator, Alcon Research, Ltd., Protocol#C-04-14
Clinical Evaluation of the Safety and Efficacy of StablEyz Intraocular Irrigating Solution compared to BSS Plus for Use During Cataract Extraction and IOL implantation.
2002 – Principal Investigator, Alcon Research, Ltd., Protocol #C-03-32
Preoperative and Postoperative use of Nepafenac Ophthalmic Suspension for the Treatment of Ocular Inflammation Associated with Cataract Surgery.
2000 – Investigator, A pregabalin open-label extension safety trial in patients with post herpetic neuralgia and painful diabetic peripheral neuropathy (neuropathic pain).
2000 – Investigator, An eight-week, double-blind, placebo-controlled trial of Pregabalin (300 mg/day) for relief of pain in patients with painful diabetic peripheral neuropathy.
1999 – Investigator, An eight-week, double-blind, placebo-controlled, parallel Group study of pregabalin in patients with post herpetic neuralgia.
1999 – Investigator, An eight-week, randomized, double-blind, placebo-controlled, monotherapy trial of pregabalin for treatment of pain associated with fibromyalgia.
1999 – Investigator, A five-week, double blind, placebo-controlled, parallel, Group Study of pregabalin 75 mg and 150 mg/day in patients with post herpetic neuralgia.
1998 – Investigator, An eight-week, randomized, double-blind, placebo-controlled, monotherapy trial of pregabalin for treatment of chronic low back pain.
